Surface Oncology
  • Home
  • About Us
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Partners
  • Pipeline & Programs
    • Pipeline
    • Posters & Publications
    • Clinical Trials
  • Investors & Media
    • News
      • Press Releases
      • Events
    • Stock Information
      • Stock Quote Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Governance
      • Documents and Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Resources
      • Investor FAQs
      • Information Request
      • Email Alerts
  • Contact
Break
Through

Limitless innovation for people with cancer

Pipeline
Pipeline

How we break through

Learn more +
News
News

Where we share the latest

Read more + Social media +
Careers
Careers

Unparalleled experience at every step

Join Us +
Surface Oncology
© 2023 Surface Oncology

SURFACE ONCOLOGY and the Surface Oncology logo are registered trademarks of Surface Oncology, Inc. All rights reserved.
50 Hampshire Street, 8th Floor
Cambridge, MA 02139
  • Privacy
  • Terms of Use
Twitter Community Guidelines
Connect with Surface
  • Twitter
  • LinkedIn
  • Instagram
  • Glassdoor

Coherus Biosciences

Surface Oncology is now a wholly owned subsidiary of Coherus Biosciences.

Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.

Coherus is developing an innovative immuno-oncology pipeline that will be synergistic with its proven commercial capabilities in oncology. Through an in-licensing agreement with Shanghai Junshi Biosciences Ltd., Coherus is developing toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for the treatment of NPC is under review by the FDA. Toripalimab is approved in China for the treatment of melanoma, urothelial cancer, esophageal squamous cell carcinoma, nasopharyngeal carcinoma and non-small cell lung cancer.

Through its acquisition of Surface Oncology, Coherus’ immuno-oncology pipeline will now include multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. Casdozokitug (SRF388) is a novel anti-IL-27 antibody currently being evaluated in Phase 1/2 clinical trials in lung and liver cancer. CHS-114 (SRF114) is a highly selective, competitively positioned anti-CCR8 antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors. There are also two out-licensed partnership programs to advance its next-generation cancer therapies.

Coherus’ earlier-stage immuno-oncology pipeline targets immune-suppressive mechanisms in the tumor microenvironment, including CHS-006, a TIGIT-targeted antibody, being evaluated in a Phase 1/2 clinical trial in combination with toripalimab in patients with advanced solid tumors, and CHS-1000, a preclinical program targeting the novel pathway ILT4.

Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis®, and YUSIMRY™ (adalimumab-aqvh), a biosimilar of Humira®.

Please see the section titled “Forward-Looking Statements” in the press release.

 

To learn more about Coherus, please visit www.coherus.com

Press Release

Surface Oncology Form 8-K

Coherus BioSciences Form 8-K

  • Home
  • About Us
  • Pipeline & Programs
  • Investors & Media
      « Back
    • Investors & Media
    • News
        « Back
      • News
      • Press Releases
      • Events
    • Stock Information
        « Back
      • Stock Information
      • Stock Quote Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Governance
        « Back
      • Governance
      • Documents and Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
        « Back
      • Financial Information
      • SEC Filings
    • Investor Resources
        « Back
      • Investor Resources
      • Investor FAQs
      • Information Request
      • Email Alerts
  • Contact